Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Kazia Therapeutics ( (KZIA) ) is now available.
On July 9, 2025, Kazia Therapeutics announced promising early results from a Phase 1b trial involving a 61-year-old patient with metastatic triple-negative breast cancer. The trial, which combines Paxalisib with pembrolizumab and chemotherapy, showed a significant reduction in circulating tumor cells and clusters after just 21 days of treatment. This outcome suggests a potential breakthrough in early intervention against systemic disease progression, aligning with preclinical findings and offering hope for improved treatment efficacy.
The most recent analyst rating on (KZIA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.
Spark’s Take on KZIA Stock
According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.
Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.
To see Spark’s full report on KZIA stock, click here.
More about Kazia Therapeutics
Kazia Therapeutics Limited is an oncology-focused drug development company based in Sydney, Australia. Their lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, targeting multiple forms of cancer. The company has been involved in several clinical trials, including those for glioblastoma and advanced breast cancer, and has received various designations from the FDA for its treatments.
Average Trading Volume: 910,175
Technical Sentiment Signal: Sell
Current Market Cap: $7.32M
For a thorough assessment of KZIA stock, go to TipRanks’ Stock Analysis page.